^
Association details:
Biomarker:SKAP2-BRAF fusion
Cancer:Melanoma
Drug:Tafinlar (dabrafenib) (BRAF inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: D – Preclinical
New
Source:
Title:

Genetic heterogeneity of BRAF fusion kinases in melanoma affects drug responses

Excerpt:
Heterogeneous patterns of drug response to RAF and MEK inhibitors of cell lines harboring BRAF fusions compared toBRAFV600E mutant lines....all tested cell lines carrying BRAF fusions were resistant to vemurafenib and dabrafenib, sharply distinguishing them from BRAFV600E mutant cell lines…
DOI:
10.1016/j.celrep.2019.09.009